To promote innovation in the biomedical industry, Taiwan continues to reinforce the R&D investment in biotechnology innovation, develop pharmaceutical products for niche markets, and focus on systemized and intelligent medical devices, in the hope of making Taiwan the hub of biomedical technology innovation in Asia-Pacific.

According to an official report on the 2017 biotechnology industry in Taiwan, the 2016 output value of the industry in Taiwan amounted to NT$315 billion, an increase of 5.5% to last year. The output value of medical devices, in particular, increased by 6.4% and reached NT$141.5 billion. If Taiwan can take advantage of its industrial clusters, it will be looking at a promising goal of NT$200 billion in medical device output value by 2020.

This year marks the 10th year of MEDiT. As a grand forum in Taiwan's medical device industry, each year, MEDiT proposes a theme in accordance with current market demands. It helps manufacturers build industrial clusters and make way into the global value chain, bringing them closer to the latest trends. Leading medical device manufacturers such as GE, Philps Healthcare, Siemens, Medtronics, J&J, and Roche Group all participated in this forum. The aim is to establish business ties and grasp industrial opportunities through this event.